MidCap Advisors, a premier middle-market investment banking firm, announced the addition of Lisa Sonneborn as a Healthcare Senior Advisor. Ms. Sonneborn's extensive experience in clinical trials and her leadership in scaling businesses will enhance MidCap Advisors' healthcare advisory services. The move is aimed at providing strategic guidance to healthcare organizations, particularly those involved in clinical research and trials.

Veeva Systems Inc., a global leader in cloud software for the life sciences industry, announced that Indero, formerly Innovaderm Research, successfully launched its 40th RTSM (Randomization and Trial Supply Management) study on Veeva RTSM. This milestone highlights the continued collaboration between the two organizations, emphasizing the efficiency and effectiveness of Veeva RTSM in driving clinical trial operations.

Biodexa Pharmaceuticals PLC, a clinical stage biopharmaceutical company, has received Fast Track designation from the FDA for its drug eRapa, a proprietary encapsulated form of rapamycin for the treatment of familial adenomatous polyposis (FAP). The company is preparing to launch a Phase 3 trial for eRapa, which aims to reduce the risk of colon cancer in patients with FAP. Biodexa has secured funding for the trial, and CROs have been appointed for both U.S. and European components.

The Advanced Kidney Cancer market is rapidly evolving with cutting-edge research and breakthrough therapies, driven by leading companies like Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, and Xencor. DelveInsight's 'Advanced Kidney Cancer Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Advanced Kidney Cancer therapies in various stages of clinical development. The report highlights 50+ active players working on 55+ pipeline drugs. Key companies include Janux Therapeutics, Infinity Pharmaceuticals, Merck Sharp & Dohme, Xencor, Exelixis, X4 Pharmaceuticals, Nykode Therapeutics, Tarus Therapeutics, AstraZeneca, RemeGen, NiKang Therapeutics, NGM Biopharmaceuticals, MedImmune, and others. The report also covers key therapies such as Savolitinib, Relatlimab, JANX008, TQB2450, Tc-99m Pentetate, BMS-986488, Belzutifan, DFF332, RAD001, PDR001, NIR178, Atezolizumab, Zanzalintinib, and others. In February 2025, Telix Pharmaceuticals announced the FDA's acceptance of the BLA for TLX250-CDx (Zircaix®), a breakthrough kidney cancer PET imaging agent.

Clinical trial tech company Clario has acquired imaging specialist NeuroRx, further strengthening its neuroscience expertise and service offerings. NeuroRx, founded by Dr. Douglas Arnold, will join Clario as a senior scientific advisor. This acquisition comes days after Clario announced the acquisition of WCG's neuro-focused eCOA business, reinforcing its commitment to neuroscience.